Back to search results

Phase 1 Study of Hezkue Turbo® (sildenafil) with Food vs. Fasting

This study is looking at how food affects a liquid form of sildenafil, called Hezkue Turbo® (ASP-001.1). Sildenafil is a medication used for erectile dysfunction. Researchers want to see how your body absorbs Hezkue Turbo® when you take it with food compared to when you haven't eaten. They will also check for any side effects like dizziness or headache. You can join if you are a healthy man between 20 and 70 years old with a healthy body weight. The study will measure how much of the drug is in your blood over 24 hours to understand how food impacts its absorption. The study is currently unclear on its recruitment status and plans to enroll 12 participants.

Study design
This is a Phase 1 study involving 12 healthy adult men. It's an open-label study, meaning you and the researchers will know which treatment you are receiving. Each participant will receive Hezkue Turbo® both with food and without food at different times.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will track drug levels in your body for 24 hours after each dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06872866

The Objective of This Phase 1 Study is to Evaluate the Food Effect of 100 mg Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fed Versus 100 mg of Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fasted Conditions in Healthy Adult Male Subjects

Recruiting
PHASE1Ages 20–70InterventionalTreatment
Aspargo Labs, Inc
~12 participants
Updated 2025-11-19 on ClinicalTrials.gov
What's tested:ASP-001.1

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Cmax
Measured over Baseline and at 26 different timepoints during the 24 hour post-dose
+4 more outcomes measured

Conditions

Erectile Dysfunction

Explore related trials

Erectile Dysfunction

Where it's being run

1 sites across 1 states
New York1

Who to contact

Mario Guralnik, PhD
[email protected]
714-818-3000
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

The participant must be informed of the nature of the study and voluntarily agree to participate by signing an informed consent form prior to any study-specific procedures.
Participants must be healthy male volunteers aged 20 to 70 years (inclusive) at the time of dosing.
Participants must have a body mass index between 18.0 and 29.9 kg/m² (inclusive) and a body weight of 50 to 100 kg (inclusive).
Participants must be judged by the Investigator or designee to be in good general health, as documented by medical history, physical examination, clinical laboratory tests, vital signs, and 12-lead electrocardiogram (ECG). Any deviations from normal ranges must be assessed and deemed not clinically significant by the Investigator or designee.
Participants must have a creatinine clearance (CrCl) value greater than 80 mL/min, as calculated by the Cockcroft-Gault equation.
Participants must agree to practice an acceptable method of contraception as outlined in the protocol.

Exclusion

Unwillingness or inability to follow the procedures specified by the protocol.
Participant received any investigational drug/product within 30 days prior to the first dose.
History of significant renal, hepatic, cardiovascular (including orthostatic hypotension), psychiatric, neoplastic, inflammatory, infectious, diabetes mellitus, or other disease which, in the opinion of the Investigator, represents a safety risk for taking part in the study.
Presence of any clinically significant results from laboratory tests, vital signs assessments, and electrocardiograms, as judged by the Investigator and/or designee.
Any degree of hepatic impairment based on liver function testing (abnormal ALT, AST, bilirubin, alkaline phosphatase, prothrombin time and international normalized ratio during screening).
Demonstrates a reactive screen for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody.
Reports a clinically significant illness during the 28 days prior to first dose (as determined by the Investigator and/or designee).
Subjects with known hypersensitivity to sildenafil or any component in the study medication, such as peppermint oil.
Reports a history of clinically significant allergies including food or drug allergies as judged by the Investigator.
History of drug abuse within the previous year, or a positive drug screen (amphetamines, barbiturates, benzodiazepines, cannabinoids, Cocaine, Opiates, Phencyclidine, 3,4-methylenedioxymethamphetamine (MDMA)) at screening and/or Day -1.
Regular alcohol consumption of \>15 units per week, with one unit being equivalent to 330 mL of beer or 125 mL of wine or 25 mL to 40 mL of ≥ 40% spirits, or a positive alcohol breathalyzer test at screening and/or Day -1.
Reports use of CYP enzyme inhibitors within 14 days prior to Period 1 dosing.
Reports use of CYP enzyme inducers or St. John's Wort within 28 days prior to Period 1 dosing.
Use of prescription or non-prescription drugs, including individual vitamins, herbal and dietary supplements within seven days or five half-lives, whichever is longer, unless in the opinion of the Investigator and Sponsor's medical monitor the medication is not expected to interfere with the study procedures or compromise subject safety (occasional use of acetaminophen, naproxen, and ibuprofen are allowed).
Blood donation or significant blood loss within 3 months before screening. All volunteers will be advised not to donate blood for 30 days after completing the study.
Reports donating plasma within 14 days prior to first dose. All volunteers will be advised not to donate plasma for 30 days after completing the study.
Demonstrates, in the opinion of study staff, inadequate veins or veins unsuitable for repeated venipuncture (e.g., veins difficult to locate, access, or puncture; veins with a tendency to rupture during or after puncture).
Reports difficulty fasting or consuming standardized meals.
Reports intolerance to fatty foods or cannot consume a high-calorie and high-fat breakfast.
Subjects who have difficulty swallowing.
Regular use of tobacco (\>4 cigarettes per day) or nicotine-containing products within four weeks before screening, or urinary cotinine level indicative of active smoking at screening and/or Day -1
Major surgery within three months or minor surgery within one month before screening as per the Principal Investigator (PI) judgment.
If, in the opinion of the PI, the subject is not suitable for the study.
Subject administered COVID-19 vaccine within three days prior to each check-in.
Subjects with retainers, braces, dentures, partial dentures, and/or tongue piercing.
Subjects using the following within 14 days of first dose:
Nitric oxide donors, such as organic nitrates or organic nitrites in any form
Antihypertensive medications
PDE5 inhibitors (e.g., sildenafil, tadalafil, vardenafil)
Systolic blood pressure: 90 - 140 mmHg
Diastolic blood pressure: 50 - 90 mmHg
Heart rate at screening: 50 - 100 beats per minute
Institutionalized volunteers.
Reports use of any hormone replacement therapy within 6 months prior to first dose.
Use of any products containing Seville oranges, grapefruit and pomelo within seven days prior to first dose and for the duration of the study.
Ingestion of any caffeine/xanthine containing products (coffee, tea, soft drinks, chocolate, energy drinks, etc.), foods containing poppy seeds within 48 hours prior to first dose and for the duration of the study.
Ingestion of any beverages containing more than 5% fruit juice (fruit drinks, fruit punches, fruit cocktails, fruit-ades, or other products containing 5% or less of fruit juice will be allowed) within 48 hours prior to first dose and for the duration of the study.

What this trial measures

  • CmaxBaseline and at 26 different timepoints during the 24 hour post-dose

    The PK profile of ASP-001.1 in healthy male subjects under fasted vs fed conditions. Calculation of maximum plasma concentration (Cmax) over the specified timeframe.

  • AUCtBaseline and at 26 different timepoints during the 24 hour post-dose

    The PK of ASP-001.1 in healthy male subjects under fasted and fed conditions. The area under the plasma concentration versus time curve from zero to infinity (AUCi) will be calculated by adding the last quantifiable concentration (Ct)/ elimination rate contant (Kel) to AUCt.

  • TmaxBaseline and at 26 different timepoints during the 24 hour post-dose

    The PK of ASP-001.1 in healthy male subjects under fasted and fed conditions. Calculation of the time of the maximum measured plasma concentration (Tmax). If the maximum plasma concentration occurs at more than one time point, the first is chosen as Tmax.

  • ThalfBaseline and at 26 different timepoints during the 24 hour post-dose

    PK of ASP-001.1 in healthy male subjects under fasted and fed conditions. The half-life will be calculated by the equation tHalf = 0.693/ Kel. Apparent elimination half-life.

  • KelBaseline and at 26 different timepoints during the 24 hour post-dose

    The PK of ASP-001.1 in healthy male subjects under fasted and fed conditions. Calculation of the terminal elimination rate constant obtained from the slope of the line, fitted by linear least squares regression, through the terminal points of the log (base e) of the concentration versus time plot for these timepoints.